Merz North America Announces FDA Approval of Xeomin (incobotulinumtoxinA) for Treatment of Adult Upper Limb Spasticity

Merz North America Announces FDA Approval of Xeomin (incobotulinumtoxinA) for Treatment of Adult Upper Limb Spasticity

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Drugs approved for various conditions also have antibiotic properties

Drugs approved for various conditions also have antibiotic properties

Novel drug shows promise in mouse models of human metastatic breast cancer

Novel drug shows promise in mouse models of human metastatic breast cancer

Bile acid may help treat fatty liver disease and obesity

Bile acid may help treat fatty liver disease and obesity

Combination treatment provides effective one-two punch against prostate cancer

Combination treatment provides effective one-two punch against prostate cancer

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

In continuation of my update on (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide), CF101

OphthaliX Inc. (OTCQB:OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT:CANF), announced today that it has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.

GlobalData estimates that the treatment market for glaucoma in the seven major markets was $2.4 billion in 2013 and will grow to approximately $3 billion by 2023. Most glaucoma drugs on the market today are generic eye drops. The key advantages of CF101 are its oral administration and excellent safety profile.

The Phase II trial is being conducted in Europe and Israel and full enrollment of 88 patients has been achieved. Top line results are expected in mid-2016. The study is being conducted with two cohorts. In the first cohort patients were treated with 1 mg CF101 and placebo. Blinded results from this cohort showed that the drug had a favorable safety profile and was well tolerated. In the second cohort, dosage was increased, with patients receiving 2 mg of CF101 and matching placebo, given orally every 12 hours for 16 weeks. The drug's mechanism of action has been validated in an article by a leading researcher from University College London in the UK, Dr. Cordiero, who showed that the A3 adenosine receptor (A3AR) agonist has a neuroprotective effect in the eye via inhibition of retinal ganglion cell apoptosis resulting in a significant decrease in intraocular pressure (IOP).

"Glaucoma is a substantial global market in which CF101 is one of only a few oral drugs in development. Oral drugs like CF101 have the potential to increase patient compliance and be more convenient for the patient," stated Dr. Pnina Fishman, Chairman and Interim CEO of OphthaliX. "In prior human clinical studies, we've seen that CF101 reduced IOP, the most important and only modifiable risk factor for glaucoma."

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

In continuation of my update on CF101

OphthaliX Inc. (OTCQB:OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT:CANF), announced today that it has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.

GlobalData estimates that the treatment market for glaucoma in the seven major markets was $2.4 billion in 2013 and will grow to approximately $3 billion by 2023. Most glaucoma drugs on the market today are generic eye drops. The key advantages of CF101 are its oral administration and excellent safety profile.

The Phase II trial is being conducted in Europe and Israel and full enrollment of 88 patients has been achieved. Top line results are expected in mid-2016. The study is being conducted with two cohorts. In the first cohort patients were treated with 1 mg CF101 and placebo. Blinded results from this cohort showed that the drug had a favorable safety profile and was well tolerated. In the second cohort, dosage was increased, with patients receiving 2 mg of CF101 and matching placebo, given orally every 12 hours for 16 weeks. The drug's mechanism of action has been validated in an article by a leading researcher from University College London in the UK, Dr. Cordiero, who showed that the A3 adenosine receptor (A3AR) agonist has a neuroprotective effect in the eye via inhibition of retinal ganglion cell apoptosis resulting in a significant decrease in intraocular pressure (IOP).

"Glaucoma is a substantial global market in which CF101 is one of only a few oral drugs in development. Oral drugs like CF101 have the potential to increase patient compliance and be more convenient for the patient," stated Dr. Pnina Fishman, Chairman and Interim CEO of OphthaliX. "In prior human clinical studies, we've seen that CF101 reduced IOP, the most important and only modifiable risk factor for glaucoma."

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD